TickerTalks
Browse all tickers →
TickerTalks›$AUC
AUAUC

ATIF Holdings Limited Ordinary Shares

$AUC·$88M·Investment - Banking & Investment Services·Financial Services
$8.52+31.1%1Y+13.0%
Mentions · last 7 days
2026-06-20: 0 posts2026-06-21: 0 posts2026-06-22: 0 posts2026-06-23: 1 posts2026-06-24: 0 posts2026-06-25: 0 posts2026-06-26: 2 posts3
Price updated 17h ago·X counts updated 17h ago
AUAUC
$AUCATIF Holdings Limited Ordinary Shares
$8.52+31.08%3 posts
AI analysisFundamentalsVoices on X
Loading…

What it does

Plain-English summary of the business — what they sell and how they make money.

ATIF Holdings Ltd. specializes in offering financial consulting services. The firm also provides dedicated business advisory, including strategic counsel for mergers and acquisitions, assistance with regulatory compliance after a company goes public, and operational management support, alongside other related solutions. This company commenced operations on January 5, 2015, and its main office is situated in Irvine, California.

Industry overviewAI analysisGenerated by AI from underlying data

Where Investment - Banking & Investment Services sits in its cycle right now — and what that implies for $AUC.

Investment - Banking & Investment Services · Financial Services

Market volatility and elevated equity activity are IBKR's structural revenue drivers — high ADV benefits the automated electronic broker while the SEC's removal of the $25K PDT rule expands the addressable retail trader population. Sustained interest rates mean interest income on client balances adds a second earnings lever.

Top industry ETF

$XLFFinancial Select Sector SPDR
-2.3%YTD
+3.4%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-2.7How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-10.4%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-218%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-17.5%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
19.1Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-33.3%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.9.7×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.—Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.—Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.—Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 10.0M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.5% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.075-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

3New insider — initial holdingsMar 273
3New insider — initial holdingsMar 273
3New insider — initial holdingsMar 273
3New insider — initial holdingsMar 273
3New insider — initial holdingsMar 273
+ 5 other (1 6-K · 1 EFFECT · 1 CORRESP · 1 UPLOAD) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapygurufocus.com·1d agoLilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLLgurufocus.com·13d agoUP Fintech: Q1 Revenue and Client Assets Grow Steadily, Total Revenue Up 26.3% YoYgurufocus.com·25d ago

More in Investment - Banking & Investment Services

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$GLXY$IBKR$BNY
Voices on X · last 7 days

No standout posts about $AUC on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport